drugset
drugset / Trial / NCT01520220

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

NCT01520220 ↗

Phase 1 Completed 100 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.

Timeline

Start
2012-06-11
Primary completion
2015-06-26
Completion
2017-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject gandotinib Small molecule — Oral

Indications

acquired polycythemia vera essential thrombocythemia myelofibrosis